2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors

US7704999B2 · kind B2 · utility

Assignee

• Bayer Schering Pharma AG · DE

Inventors

• Ulrich Niewohner · Wermelskirchen, DE
• Mazen Es-Sayed · Langenfeld, DE
• Helmut Haning · Milford, US
• Thomas Schenke · Odenthal, DE
• Karl-Heinz Schlemmer · Wuppertal, DE
• Jörg Keldenich · Wuppertal, DE
• Erwin Bischoff · Wuppertal, DE
• Elisabeth Perzborn · Wuppertal, DE
• Klaus Dembowsky · Boston, US
• Peter Serno · Bensberg, DE
• Marc Nowakowski · Wuppertal, DE

Key dates

• Filing date: Dec 21, 2007
• Grant date: Apr 27, 2010
• Expiry date: Dec 21, 2027

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07F9/6561
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The 2-phenyl-substituted imidazotriazinones having short, unbranched alkyl radicals in the 9-position are prepared from the corresponding 2-phenyl-imidazotriazinones by chlorosulphonation and subsequent reaction with the amines. The compounds inhibit cGMP-metabolizing phosphodiesterases and are suitable for use as active compounds in pharmaceuticals, for the treatment of cardiovascular and cerebrovascular disorders and/or disorders of the urogenital system, in particular for the treatment of erectile dysfunction.